Cara Cassino, M.D.

Cara Cassino, M.D.

Member of the Interim Office of the Chief Executive Officer,
Chief Medical Officer and Executive Vice President of Research and Development

Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and globally. Prior to joining ContraFect, Dr. Cassino served as Senior Vice President at Forest Laboratories, Inc (acquired by Actavis plc, now Allergan plc), where she oversaw Global Clinical Development. While at Forest, she was responsible for pre- and post-marketing clinical activities for a portfolio of 35 compounds, and also clinical due diligence for M&A activity including the $2.9 billion acquisition of Aptalis Pharma and the $1.1 billion acquisition of Furiex Pharmaceuticals. Previously, Dr. Cassino held a number of senior executive positions at Pfizer, including Global Medical Team Leader of Pfizer's antibacterial franchise which included Zyvox (linezolid) and Medical Development Group VP for Pulmonary Vascular Disease and Rare Diseases. Dr. Cassino also served as Executive Medical Director for the late stage US respiratory franchise at Boehringer-Ingelheim Pharmaceuticals, Inc, and was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at New York University School of Medicine.

Dr. Cassino received her BA, summa cum laude, in Chemistry and Fine Arts from New York University (NYU) where she was elected Phi Beta Kappa, followed by an M.D. from NYU School of Medicine. Dr. Cassino completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital and a fellowship in Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Center. Dr Cassino is Board Certified in both internal medicine and pulmonary medicine.